Want to see GB:CREO full AI Analyst Report?
CREO Stock Chart & Stats
13.62 p
0.13 p(0.92%)
At close: 4:00 PM EDT
13.62 p
0.13 p(0.92%)
Day’s Range― - ―
52-Week Range9.52 p - 18.50 p
Previous CloseN/A
Volume174.00K
Average Volume (3M)975.48K
Market Cap
£55.69M
Enterprise Value32.53 p
Total Cash (Recent Filing)£12.40M
Total Debt (Recent Filing)£4.10M
Price to Earnings (P/E)9.7
Beta1.05
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding449,139,980
10 Day Avg. Volume668,834
30 Day Avg. Volume975,484
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.82
Price to Sales (P/S)6.81
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£9.10M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageRelatively low leverage gives Creo financial flexibility while it scales its medical-device platform. A modest debt burden reduces refinancing pressure and leaves more capacity to fund commercial expansion, provided losses do not persist indefinitely.
Recurring Consumables ModelConsumables can create repeat purchases after hospitals install the CROMA platform, improving customer retention and revenue visibility. This installed-base model may support durable growth as adoption expands across endoscopy sites and procedure volumes increase.
2025 Revenue MomentumThe stronger 2025 revenue performance indicates improving commercial traction after a flat 2024. Sustained adoption of CROMA systems and related instruments could help Creo move toward operating leverage as sales scale across its target markets.
Bears Say
Persistent Operating LossesLarge recurring EBIT and EBITDA losses show that the cost base remains well ahead of revenue scale. Unless commercial growth produces meaningful operating leverage, continued losses could constrain investment capacity and delay a sustainably profitable business model.
Negative Cash GenerationPersistent negative operating and free cash flow means Creo is not yet self-funding its operations. Even with reduced recent cash burn, prolonged outflows increase reliance on existing liquidity or future financing and can dilute flexibility during expansion.
Volatile Revenue And Earnings QualityUneven revenue performance makes the pace of commercial adoption difficult to establish, while positive net income alongside heavy operating losses suggests non-operating items influenced results. This reduces confidence that reported earnings yet reflect durable core profitability.
Creo Medical News
CREO FAQ
What was Creo Medical Group PLC’s price range in the past 12 months?
Creo Medical Group PLC lowest share price was 9.52 p and its highest was 18.50 p in the past 12 months.
What is Creo Medical Group PLC’s market cap?
Creo Medical Group PLC’s market cap is £55.69M.
When is Creo Medical Group PLC’s upcoming earnings report date?
Creo Medical Group PLC’s upcoming earnings report date is Sep 30, 2026 which is in 44 days.
How were Creo Medical Group PLC’s earnings last quarter?
Creo Medical Group PLC released its earnings results on May 22, 2026. The company reported -0.028 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Creo Medical Group PLC overvalued?
According to Wall Street analysts Creo Medical Group PLC’s price is currently Overvalued.
Does Creo Medical Group PLC pay dividends?
Creo Medical Group PLC does not currently pay dividends.
What is Creo Medical Group PLC’s EPS estimate?
Creo Medical Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Creo Medical Group PLC have?
Creo Medical Group PLC has 449,139,980 shares outstanding.
What happened to Creo Medical Group PLC’s price movement after its last earnings report?
Creo Medical Group PLC reported an EPS of -0.028 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 27.473%.
Which hedge fund is a major shareholder of Creo Medical Group PLC?
Currently, no hedge funds are holding shares in GB:CREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Creo Medical Stock Smart Score
Company Description
Creo Medical Group PLC
Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquartered in Chepstow, the company's core offering is Croma, an advanced energy platform. This platform is engineered to power a diverse collection of multi-modal instruments, thereby enhancing therapeutic interventions for both medical professionals and patients. Its extensive product portfolio includes specialized tools such as Speedboat Inject, an adaptable energy instrument designed for flexible endoscopic procedures; Speedboat Slim, a flexible bipolar radiofrequency (RF) and microwave device for precise tissue cutting and coagulation; MicroBlate Fine, a microwave needle for ablation; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device engineered to control upper and lower gastrointestinal bleeds; and SpydrBlade Flex, a flexible scissor-like instrument that integrates bipolar RF and microwave technology to grasp, cut, and coagulate highly vascularized tissues.